Market Overview

Viracor Eurofins Announces Medical Advisory Board

Share:

Viracor Eurofins Announces Medical Advisory Board

Industry-leading infectious disease and transplant physicians help Viracor ideate and innovate to serve unmet testing needs, improving patient care and outcomes

PR Newswire

LEE'S SUMMIT, Mo., Aug. 21, 2018 /PRNewswire/ -- Viracor Eurofins, a leader in infectious disease, immunology and allergy testing and biopharma services with fast result turnaround time, is pleased to announce the formation of its Medical Advisory Board.  Inaugural Board members include:

  • Michael G. Ison, MD, MS, Medical Director, Transplant and Immunocompromised Host Infectious Diseases; Professor of Medicine (Infectious Diseases) and Surgery (Organ Transplantation) at Northwestern Memorial Hospital.
  • Michele Morris, MD, Director, Immunocompromised Host Section, Division of Infectious Disease affiliated with Jackson Memorial Hospital, University of Miami Hospital and Clinics and University of Miami Sylvester Comprehensive Cancer Center.
  • Betsy Herold, MD, Chief, Division of Pediatric Infectious Diseases, Department of Pediatrics at Albert Einstein College of Medicine and The Children's Hospital at Montefiore.

https://www.viracor-eurofins.com (PRNewsfoto/Viracor Eurofins)" alt="With over 30 years of specialized expertise in infectious disease, immunology and allergy testing for immunocompromised and critical patients, Viracor Eurofins is committed to helping medical professionals, transplant teams, reference labs and biopharmaceutical companies get results faster, when it matters most. https://www.viracor-eurofins.com (PRNewsfoto/Viracor Eurofins)">

As the company pursues its vision to be the most trusted laboratory partner improving patient care through innovative testing services, Viracor looks forward to working with these leaders in their respective fields. The Board will meet regularly to discuss clinical needs and insights in an effort to bring even more innovative diagnostic tests and services to hospitals and physicians.

"We are honored to partner with such highly regarded physicians who bring years of expertise and insights on the clinical and diagnostic needs facing immunocompromised patients, to further Viracor's efforts in innovating infectious disease diagnostics, improving patient care," said David Morgan, President, Viracor Eurofins.

Visit www.viracor-eurofins.com for the complete bios of the Medical Advisory Board and for more information on Viracor Eurofins.

About Viracor Eurofins
With over 30 years of specialized expertise in infectious disease, immunology and allergy testing for immunocompromised and critical patients, Viracor Eurofins is committed to helping medical professionals, transplant teams, reference laboratories and biopharmaceutical companies get results faster, when it matters most. Viracor is passionate about delivering value to its clients by providing timely, actionable information, never losing sight of the connection between the testing it performs and the patients it ultimately serves.

Viracor is a 100 percent subsidiary of Eurofins Scientific (EUFI.PA), the global leader in bio-analytical testing, and one of the world leaders in genomic services. For more information, please visit www.eurofins.com and www.viracor-eurofins.com.

About Eurofins - A global leader in bio-analysis
Eurofins Scientific through its subsidiaries (hereinafter sometimes "Eurofins" or "the Group") believes it is a scientific leader in food, environment and pharmaceutical products testing and in agroscience CRO services. It is also one of the independent market leaders in certain testing and laboratory services for genomics, discovery pharmacology, forensics, CDMO, advanced material sciences and for supporting clinical studies. In addition, Eurofins is one of the emerging players in specialty clinical diagnostic testing in Europe and the USA. With over 38,000 staff in more than 400 laboratories across 44 countries, Eurofins offers a portfolio of over 150,000 analytical methods for evaluating the safety, identity, composition, authenticity, origin and purity of biological substances and products, as well as for innovative clinical diagnostic. The Group objective is to provide its customers with high-quality services, accurate results on time and expert advice by its highly qualified staff.

Eurofins is committed to pursuing its dynamic growth strategy by expanding both its technology portfolio and its geographic reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology and analytical chemistry to offer its clients unique analytical solutions and the most comprehensive range of testing methods.

As one of the most innovative and quality oriented international players in its industry, Eurofins is ideally positioned to support its clients' increasingly stringent quality and safety standards and the expanding demands of regulatory authorities around the world.

The shares of Eurofins Scientific are listed on the Euronext Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg ERF FP).

 

Cision View original content with multimedia:http://www.prnewswire.com/news-releases/viracor-eurofins-announces-medical-advisory-board-300700547.html

SOURCE Viracor Eurofins

View Comments and Join the Discussion!